Zacks.com on MSN6d
MRK's sNDA for Welireg in Rare Tumors Gets FDA's Priority Tag
The FDA accepts and grants priority review to Merck's sNDA for Welireg to treat advanced pheochromocytoma and paraganglioma.
Alnylam Pharmaceuticals' SWOT analysis: stock poised for growth amid ATTR-CM opportunity
Alnylam Pharmaceuticals , Inc. (NASDAQ:ALNY), a leader in RNA interference (RNAi) therapeutics, stands at a pivotal juncture as it seeks to capitalize on the burgeoning market for ...
Business Wire4d
Securities Commission of The Bahamas
$221.55 million regulatory claim against FTX DM. The Court-approved “Claim Subordination Agreement” between the JOLs and the Commission enables the reprioritisation of the payment of all ...
Le Lézard11d
FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
Biogen Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) and the European Medicines Agency (EMA) has validated the ...
Business Wire4d
Supreme Court Sanctions Agreement for FTX DM Joint Official Liquidators to Subordinate Securities Commission of The Bahamas’ $221.55 Million Regulatory Penalties Claim
$221.55 million regulatory claim against FTX DM. The Court-approved “Claim Subordination Agreement” between the JOLs and the Commission enables the reprioritisation of the payment of all ...
BioSpace11d
Biogen Trims Research Workforce, Higher-Dose SMA Drug Accepted for Regulatory Review
In a good-news-bad-news week for Biogen, the company will cut an undisclosed number of employees, just as a higher dose of ...
Business Wire9d
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Pres…
Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of ...
Biogen Inc.: FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMA CAMBRIDGE, Mass., Jan. 2 ...